NC 2500Alternative Names: NC-2500
Latest Information Update: 16 Jul 2016
Price : $50
At a glance
- Originator Nippon Chemiphar
- Mechanism of Action Xanthine dehydrogenase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Hyperuricaemia
Highest Development Phases
- No development reported Hyperuricaemia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Hyperuricaemia in Japan
- 10 Jul 2013 NC 2500 is available for licensing as of 31 Mar 2013.
- 31 Mar 2013 Phase-I clinical trials in Hyperuricaemia in Japan (unspecified route)